Abstract: The present invention relates to immunogenic polypeptide fragments of a human Arginase protein. The fragments are in particular useful for the treatment or prevention of cancer.
Abstract: Naphthalimide compounds as used in tissue bonding and protein cross-linking applications. When activated by an activating agent, such as light in the 400-500 nm absorption range, the naphthalimide compounds form chemically-reactive species that cross-link proteins, bond connective tissues together, and bone tissues and other biomaterials together. A naphthalimide-labeled biomolecule, such as a naphthalimide-labeled chitosan, is also capable of bonding tissues without subsequent direct illumination of the contacted tissue area. The naphthalimide compounds may be used in tissue or arterial repair, stabiliation of an expanded arterial wall after angioplasty, tethering pharmaceutical agents to tissue surfaces to provide local drug delivery, and for chemically bonding skin care products, sunscreens, and cosmetics to the skin.
Type:
Grant
Filed:
August 20, 2018
Date of Patent:
December 1, 2020
Assignee:
Alumend, LLC
Inventors:
Ronald E. Utecht, Kaia L. Kloster, Millard M. Judy, Kevin J. Vaska, James L. Matthews
Abstract: The present invention is produced as a polymerized peptide prepared by oxidatively cross-linking collagen-like peptides having the triple-helical structure containing three peptide chains each containing multiple cysteine (Cys) residues. This polymerized peptide can be processed into a hydrogel and a thin membrane sheet before use, and is capable of imparting a particular physiological function such as cellular adhesion by incorporating functional amino acid sequences present on biological polymers. Further, the present invention provides a method for producing the abovementioned polymerized peptide and the like; and use applications employing the same, such as cell culturing, wound dressing, and compositions including regenerative medical materials and research materials.
Type:
Grant
Filed:
June 23, 2016
Date of Patent:
December 1, 2020
Assignee:
KOLA-GEN PHARMA, INC.
Inventors:
Takaki Koide, Shinichiro Ichise, Shungo Takeuchi, Hiroshi Nose
Abstract: The present disclosure relates to a method of treating a patient experiencing hypotension, comprising genotyping for a TT, AA, or AT genotype, and administering a therapeutically effective amount of vasopressin based on genotype to maintain a target blood pressure.
Abstract: The invention provides a method of treating a degenerative joint disease. The method comprises administering an effective amount of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP). The invention also provides a pharmaceutical product as well as a kit comprising DA-DKP.
Abstract: The invention concerns novel streptavidin muteins. In one embodiment such a mutein (a) contains two or more mutations in the region of the amino acid positions 117 to 121 with reference to the amino acid sequence of wild type streptavidin of which amino acid residues 14 to 139 are as set forth at SEQ ID NO:212 and (b) has a higher binding affinity than each of (i) a streptavidin mutein “1” (SEQ ID NO: 16) that comprises the amino acid sequence Val44-Thr45-Ala46-Arg47 (SEQ ID NO: 98), or (ii) wild type-streptavidin of which amino acid residues 14 to 139 are shown as SEQ ID NO: 212 for peptide ligands comprising the amino acid sequence Trp-Ser-His-Pro-Gln-Phe-Glu-Lys (SEQ ID NO: 100).
Abstract: A method of increasing muscle mass and strength in mammals by orally administering a therapeutically effective amount of phosphatidic acid. The phosphatidic acid is preferably administered as a plurality of doses per day with at least one dose being administered during the anabolic window following exercise. Preferably, the method further includes the cotemporaneous administration of a therapeutically effective amount of creatine, optionally as phosphatidylcreatine. In addition or in the alternative, the method further includes the cotemporaneous administration of a therapeutically effective amount of leucine, optionally as phosphatidylleucine.
Type:
Grant
Filed:
May 31, 2013
Date of Patent:
November 17, 2020
Assignee:
Sports Nutrition Research, LTD.
Inventors:
Robert Clarke, Matthew Cahill, Brian Sweet
Abstract: Systems and methods for acquiring, preserving, and administering delipidated plasma. Extracted delipidated plasma, comprising pre-beta HDL, is obtained and are spot tested to establish baseline amounts or concentrations of pre-beta HDL. The batches are subjected to preservation, stored, and then prepared again for use at some later date. A portion of the batch may be tested again to determine if the pre-beta HDL in the delipidated plasma has degraded or is no longer effective.
Type:
Grant
Filed:
December 19, 2018
Date of Patent:
November 3, 2020
Assignee:
HDL Therapeutics, Inc.
Inventors:
Hollis Bryan Brewer, Jr., Michael M. Matin
Abstract: Combination compositions comprising self-assembling peptides and payload agents, and methods of making and using such compositions, are described.
Type:
Grant
Filed:
December 29, 2016
Date of Patent:
October 27, 2020
Assignees:
3-D Matrix, Ltd., Vicus Therapeutics, LLC
Abstract: The present invention provides bis-polymer lipid-peptide conjugates containing a hydrophobic block and headgroup containing a helical peptide and two polymer blocks. The conjugates can self-assemble to form helix bundle subunits, which in turn assemble to provide micellar nanocarriers for drug cargos and other agents. Particles containing the conjugates and methods for forming the particles are also disclosed.
Type:
Grant
Filed:
April 24, 2018
Date of Patent:
October 20, 2020
Assignee:
The Regents of the University of California
Inventors:
Ting Xu, He Dong, Jessica Shu, Nikhil Dube
Abstract: The present application relates to novel methods for preventing, slowing the progression of, or treating nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), and/or liver fibrosis, and/or reducing the risks of liver cancer in subjects, such as HIV-infected subjects, using a GHRH molecule, e.g., trans-3-hexenoyl-GHRH(1-44)-NH2, or a pharmaceutically acceptable salt thereof. The subjects may have particular pathological features such as liver fibrosis, a hepatic fat fraction (HFF) of at least about 10%, serum alanine aminotransferase (ALT) levels of at least about 30 U/L, and/or a NAFLD Activity Score (NAS) of at least 4 or 5.
Abstract: The present invention relates to a polymeric human growth hormone prodrug and dry, liquid and reconstituted pharmaceutical formulations comprising said prodrug. It furthermore relates to their use as medicaments for the treatment of diseases which can be treated with growth hormone and to methods of treatment. It also relates to methods of application of such polymeric human growth hormone prodrug or pharmaceutical formulation.
Type:
Grant
Filed:
November 17, 2015
Date of Patent:
October 13, 2020
Assignee:
Ascendis Pharma Endocrinology Division
Inventors:
Thomas Kurpiers, Harald Rau, Evelyn Exner, Steen Jensen, Grethe Nørskov Rasmussen, Torben Lessmann, Thomas Wegge, Alina Hermann, Nina Schubert, Anna Splanemann, Joachim Zettler
Abstract: Presented herein are cyclic peptides that specifically bind to a cell surface molecule, thereby allowing cell/tissue-specific targeting. The cyclic peptides can be attached to an agent, for example, a polypeptide such as an antibody, e.g., a cell-penetrating antibody. Cyclic peptide-containing cell/tissue-specific cell-penetrating antibodies described herein are capable of targeted delivery in a cell type-specific or tissue-specific (i.e., cell/tissue-specific) manner. The cell/tissue-specific cell-penetrating antibodies described herein can be used as an effective anticancer agent for cancer that overexpresses a cell membrane protein that specifically binds to the fused cyclic peptides.
Type:
Grant
Filed:
June 20, 2019
Date of Patent:
September 29, 2020
Assignee:
ORUM THERAPEUTICS INC.
Inventors:
Yong Sung Kim, Ji Sun Kim, Jae Yeong Park, Seong Wook Park, Sei Yong Jun, Dong-Ki Choi
Abstract: The present invention relates to an oligopeptide and conjugates thereof. The present invention also relates to the use of these oligopeptide conjugates for treating or diagnosing disorders mediated by amyloid ? deposits. Finally, the present invention also relates to a coupling method for obtaining oligopeptide coupled with a substance of interest (functional conjugates).
Type:
Grant
Filed:
November 13, 2014
Date of Patent:
September 29, 2020
Assignees:
F. HOFFMANN-LA ROCHE AG, INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
Inventors:
Pierre Lafaye, Sylvie Bay, Benoit Delatour, Marc Dhenain, Charles Duyckaerts, Tengfei Li, Matthias Vandesquille, Christian Czech, Fiona Grueninger
Abstract: Compositions and methods are provided for treating a patient suffering from a disease associated with endothelial dysfunction by administering to the patient a pharmaceutical composition containing an effective amount of a synthetic collagen binding peptidoglycan.
Abstract: Provided are knottin-drug conjugates. The conjugates include a knottin peptide that includes an engineered loop that binds to a target on a cancer cell surface, and a drug (e.g., a nucleoside drug) conjugated to the knottin peptide through a linker. Also provided are pharmaceutical compositions and kits that include the knottin-drug conjugates, as well as methods of using the knottin-drug conjugates, e.g., for therapeutic purposes.
Type:
Grant
Filed:
March 14, 2017
Date of Patent:
September 8, 2020
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Nicholas Cox, Jennifer R. Cochran, Mark Smith, James R. Kintzing
Abstract: The present disclosure provides pharmaceutical compositions comprising fibronectin based scaffold domain proteins that bind, for example, proprotein convertase subtilisin kexin-9 (PCSK9).
Abstract: Methods and compositions are provided for treating and preventing preterm labor using liposome encapsulated tocolytic agents, such as indomethacin. In certain aspects, targeted liposomes are provided that allow delivery of tocolytic agents directly to the uterus, such as by targeting to the oxytocin receptor.
Type:
Grant
Filed:
December 19, 2016
Date of Patent:
August 11, 2020
Assignees:
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMS, THE METHODIST HOSPITAL
Inventors:
Jerrie S. Refuerzo, Biana Godin, Monica Longo
Abstract: The present invention provides a peptide at least partially derivable from human Thyroid Stimulating Hormone Receptor (TSHR) which peptide is capable of binding to an MHC molecule in vitro and being presented to a T cell without further antigen processing. The present invention also relates to the use of such peptides for the prevention or suppression of activating autoantibody formation in Graves' Disease.